Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEterna Therapeutics Inc

Eterna Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.99 USD -0.03 ( 1.49%)
Last update at 2026-11-04T18:45:00Z
VOLUME
11607
Market Cap
5.56M

Momentum Score

…

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.94
Low
2.04
High
52 Week Price Range
0.18
Low
4.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eterna Therapeutics Inc (ERNA) is a publicly listed biopharmaceutical company; publicly available information about its pipeline, assets and operations is limited. Long-term growth appears to depend on clinical development progress, regulatory milestones and commercial or licensing partnerships that could support revenue generation if successful.
Principal risks include early-stage development and execution risk, significant financing needs, the high probability of clinical or regulatory setbacks and limited public disclosure that hampers thorough evaluation.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.02
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.20
ROE
-686.69%
Net Debt
-1.39M
ROCE
-342.48%
Diluted EPS TTM
-2.24

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -14.13M -44.51M -21.67M -24.53M -122.30M
Net income -14.10M -44.54M -21.67M -24.58M -122.31M
Selling general administrative 5.16M 13.13M 14.59M 16.84M 14.72M
Selling and marketing expenses - - 0.00M - -
Gross profit -0.26M 0.49M -0.17M - -5.76M
Reconciled depreciation 0.26M 1.64M 0.73M 0.50M 0.46M
Ebit -9.32M -37.76M -21.06M -33.22M 68.34M
Ebitda -9.06M -36.12M -19.93M -32.03M 68.80M
Depreciation and amortization 0.26M 1.64M 1.12M 1.19M 0.46M
Operating income -9.32M -15.67M -21.14M -33.22M 68.34M
Other operating expenses 9.32M 16.26M 21.20M 27.23M 27.43M
Interest expense 0.03M 6.75M 0.61M 0.03M 0.07M
Tax provision -0.04M 0.03M 0.04M 0.04M 0.01M
Interest income 0.08M 0.25M 0.14M - -
Net interest income 0.06M -6.50M -0.09M -0.03M -0.07M
Income tax expense -0.04M 0.03M -0.00M 0.04M 0.01M
Total revenue 0.00M 0.58M 0.07M 0.00M 0.00M
Total operating expenses 9.06M 16.16M 20.97M 27.23M 27.43M
Cost of revenue 0.26M 0.10M 0.24M - 5.76M
Total other income expense net -4.81M -28.84M -0.54M 8.68M -190.64M
Net income from continuing ops -14.08M -44.54M -20.00M -24.58M -122.31M
Net income applicable to common shares - - - -24.59M -122.56M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.83M 5.27M 49.13M 22.28M 32.43M
Intangible assets - - - - 6.86M
Other current assets 1.15M 0.19M 1.60M 2.23M 1.10M
Total liab 3.43M 3.57M 46.90M 10.17M 25.93M
Total stockholder equity 2.40M 1.70M 2.23M 12.11M 6.50M
Deferred long term liab - - - - 5.99M
Other current liab 1.77M 1.01M 3.10M 3.99M 0.25M
Common stock 0.04M 0.26M 0.03M 0.03M 0.26M
Capital stock 0.04M 0.26M 0.03M 0.03M 0.26M
Retained earnings -245.64M -231.54M -186.98M -165.30M -159.70M
Other liab - - - 1.63M 0.05M
Good will 2.04M 2.04M 2.04M 2.04M 2.04M
Other assets - - - 5.23M 0.00M
Cash 1.88M 1.73M 7.58M 11.45M 16.98M
Total current liabilities 3.11M 2.94M 6.57M 7.65M 3.68M
Current deferred revenue - - 0.19M - 1.25M
Net debt -1.39M -1.04M 34.27M -7.31M -14.26M
Short term debt 0.21M 0.21M 2.22M 2.04M 0.43M
Short long term debt - - - 1.75M -
Short long term debt total 0.49M 0.68M 41.84M 4.14M 2.72M
Other stockholder equity 248.00M 232.98M 189.19M 177.38M 165.94M
Property plant equipment - - - 1.27M 3.24M
Total current assets 3.13M 2.35M 9.60M 13.68M 18.77M
Long term investments - - 0.00M 0.06M 1.00M
Net tangible assets - - - 10.06M 23.46M
Net receivables 0.10M 0.44M 0.42M 0.95M 0.68M
Long term debt - - 6.77M 1.21M -
Inventory - - - -0.95M -
Accounts payable 1.12M 1.72M 1.07M 1.62M 1.75M
Accumulated other comprehensive income - - -0.00M - -
Non currrent assets other 0.11M 0.12M 0.12M 5.23M 0.52M
Non current assets total 2.70M 2.92M 39.53M 8.60M 13.66M
Capital lease obligations 0.49M 0.68M 35.07M 1.18M 2.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.36M 0.13M -0.05M -22.74M
Change to liabilities - - - 2.03M -0.48M
Total cashflows from investing activities -0.04M -0.36M -0.02M -0.05M -22.74M
Net borrowings 2.25M 5.29M 16.50M -0.00M -0.94M
Total cash from financing activities 7.21M 6.26M 16.56M 19.58M 61.59M
Change to operating activities - - - 1.68M -1.15M
Net income -14.08M -44.54M -21.67M -24.58M -122.31M
Change in cash 0.15M -9.94M -3.87M -1.44M 15.36M
Begin period cash flow 1.73M 11.67M 15.54M 16.98M 1.63M
End period cash flow 1.88M 1.73M 11.67M 15.54M 16.98M
Total cash from operating activities -7.02M -15.84M -20.41M -20.98M -23.49M
Issuance of capital stock 4.93M 1.14M 8.03M 19.71M 62.52M
Depreciation 0.26M 1.64M 1.12M 0.50M 0.46M
Other cashflows from investing activities - 0.00M - - -
Dividends paid - 0.02M 0.02M -0.02M -0.01M
Change to inventory - - - - 0.48M
Change to account receivables -0.41M -0.01M 0.53M - -0.66M
Sale purchase of stock - - -16.25M - -22.85M
Other cashflows from financing activities - 0.97M -0.25M -0.11M 0.01M
Change to netincome - - - -0.60M 100.89M
Capital expenditures 0.04M 0.37M 0.02M 0.30M 0.15M
Change in working capital -0.05M -1.98M -2.12M 3.71M -2.35M
Stock based compensation 1.50M 1.52M 1.24M 2.94M 5.24M
Other non cash items 5.36M 27.52M 1.01M -3.54M 86.12M
Free cash flow -7.05M -16.20M -20.43M -21.27M -23.64M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ERNA
Eterna Therapeutics Inc		 -0.03
1.49%		 1.99 - - 1275.37 2.36 4581.99 -0.29
NVO
Novo Nordisk A/S		 2.50
6.21%		 42.69 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 18.19
3.43%		 548.95 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -29.09
2.99%		 944.27 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Eterna Therapeutics Inc

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

1035 Cambridge Street, Cambridge, MA, United States, 02141

617 798 6700

https://www.ernexatx.com

5

Name Title Year Born
Dr. Roger Sidhu M.D. Chief Medical Officer 1976
Dr. Matthew Angel Ph.D. CEO & Director 1981
Mr. Andrew C. Jackson Chief Financial Officer 1969
Dr. Monil Shah M.B.A., Pharm.D. Chief Operating Officer NA
Ms. Sandra M. Gurrola Principal Accounting Officer & VP of Fin. 1967
Ms. Lynn Sadowski Mason M.S. Exec. VP of Clinical Operations 1979
Ms. Susan McClatchey VP & Head of Quality NA
Ms. Sandra M. Gurrola Principal Financial & Accounting Officer and Senior VP of Finance 1967
Mr. Sanjeev Luther CEO, President & Director 1962
Ms. Dorothy J. Clarke General Counsel & Director 1966

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…